|
|
||||||||||
Research Articles |
The beneficial effects of aspirin and ACE inhibitors in CHF have been well established; however, the clinical relevance of the drug interaction between these agents remains controversial. The exact mechanism of this interaction is not known, but the proposed theory involves the opposing effects of aspirin and ACE inhibitors on prostaglandins. The medical literature dose not provide a clear picture of the clinical significance of concomitant aspirin and ACE inhibitor therapy. Some studies suggest that the dose of aspirin may influence the clinical relevance of this interaction. Short-term use of aspirin > or = 300 mg was found to attenuate enalapril's effect on hemodynamic variables. However, short-term use of low-dose aspirin (236 mg) produced no effect on blood pressure. Patients with CHF who require therapy with both aspirin and ACE inhibitors may want to consider low doses of aspirin with active monitoring of hemodynamic parameters. However, chronic aspirin therapy in patients with CHF on concomitant ACE inhibitors has not been adequately studied at this time. Data concerning a possible interaction between angiotensin II receptor antagonists and aspirin are not available. However, because angiotensin II receptor antagonists do not interfere with kininase II activity, it would seem unlikely that aspirin would interact similarly with an angiotensin II receptor antagonist. Further studies are needed to examine the exact mechanism of the interaction between aspirin and ACE inhibitors. These studies should focus on the effects of different doses of aspirin given concomitantly with ACE inhibitors in patients with CHF. Prospective, randomized studies are also needed to determine the long-term effects of aspirin and ACE inhibitor therapy on mortality in patients with CHF.
This article has been cited by other articles:
![]() |
J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine J. Am. Coll. Cardiol., August 14, 2007; 50(7): e1 - e157. [Full Text] [PDF] |
||||
![]() |
J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine J. Am. Coll. Cardiol., August 14, 2007; 50(7): 652 - 726. [Full Text] [PDF] |
||||
![]() |
T. Dolezal Review: Imidapril in Heart Failure Journal of Renin-Angiotensin-Aldosterone System, September 1, 2006; 7(3): 146 - 154. [Abstract] [PDF] |
||||
![]() |
K Dubey, D K Balani, and K K Pillai Potential adverse interaction between aspirin and Lisinopril in hypertensive rats Human and Experimental Toxicology, March 1, 2003; 22(3): 143 - 147. [Abstract] [PDF] |
||||
![]() |
P A Poole-Wilson, B F Uretsky, K Thygesen, J G F Cleland, B M Massie, and L Ryden Mode of death in heart failure: findings from the ATLAS trial Heart, January 1, 2003; 89(1): 42 - 48. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. H. Jamali, W. H. W. Tang, U. N. Khot, and M. B. Fowler The Role of Angiotensin Receptor Blockers in the Management of Chronic Heart Failure Arch Intern Med, March 12, 2001; 161(5): 667 - 672. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Braunwald, E. M. Antman, J. W. Beasley, R. M. Califf, M. D. Cheitlin, J. S. Hochman, R. H. Jones, D. Kereiakes, J. Kupersmith, T. N. Levin, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-st-segment elevation myocardial infarction: A report of the american college of cardiology/ american heart association task force on practice guidelines (committee on the management of patients with unstable angina) J. Am. Coll. Cardiol., September 1, 2000; 36(3): 970 - 1062. [Full Text] [PDF] |
||||